Virulent Mycobacterium fortuitum restricts NO production by a gamma interferon-activated J774 cell line and phagosome-lysosome fusion by Silva, Tania Regina Marques da et al.
INFECTION AND IMMUNITY, Oct. 2002, p. 5628–5634 Vol. 70, No. 10
0019-9567/02/$04.000 DOI: 10.1128/IAI.70.10.5628–5634.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Virulent Mycobacterium fortuitum Restricts NO Production by a Gamma
Interferon-Activated J774 Cell Line and Phagosome-Lysosome Fusion
Taˆnia Regina Marques da Silva,1 Juliana Ribeiro de Freitas,1,2 Queilan Chagas Silva,1,2
Cla´udio Pereira Figueira,1 Eliana Roxo,3 Sylvia Cardoso Lea˜o,4
Luiz Antoˆnio Rodrigues de Freitas,1,2
and Patrícia Sampaio Tavares Veras1,5*
Laborato´rio de Patologia e Biologia Celular, CPqGM, FIOCRUZ/BA,1 Faculdade de Medicina, Universidade Federal da Bahia,2
and Escola Bahiana de Medicina e Sau´de Pu´blica-SSA-BA,5 Bahia, and Instituto Biolo´gico, SP-SP,3 and
Departamento de Microbiologia, Imunologia e Parasitologia, Escola Paulista de Medicina,
Universidade Federal de Sa˜o Paulo, UNIFESP/EPM,4 Sa˜o Paulo, Brazil
Received 1 March 2002/Returned for modification 7 May 2002/Accepted 9 July 2002
The virulence of different isolates of Mycobacterium has been associated with two morphologically distin-
guishable colonial variants: opaque (SmOp) and transparent (SmTr). In this report we used an in vitro assay
to compare macrophage (M) responses to SmOp and SmTr Mycobacterium fortuitum variants, taking advan-
tage of the fact that these variants were derived from the same isolate. Cells preactivated or not with gamma
interferon (IFN-) were infected with SmOp or SmTr M. fortuitum. We showed that SmOp and SmTr induced
different levels of nitric oxide (NO) production by IFN--stimulated M. Indeed, the amount of IFN--induced
NO production by J774 cells was 4.8 to 9.0 times higher by SmOp (23.1 to 37.7 M) compared to SmTr
infection (3.9 to 4.8 M) (P  0.0332), indicating that virulent SmTr bacilli restricted NO production. In
addition, IFN--induced NO production by M was higher when correlated with reduction of only avirulent
SmOp bacillus viability. SNAP (S-nitroso-N-acetyl-DL-penicillamine)-induced NO production did not modify
SmTr viability, indicating its resistance to nitrogen radicals. Electron microscopy studies were performed to
evaluate the capacity of phagosomes to fuse with lysosomes labeled with bovine serum albumin-colloidal gold
particles. By 24 h postinfection, 69% more phagosome-containing SmOp variant had fused with lysosomes
compared to the SmTr-induced phagosomes. In conclusion, these data indicate that virulent SmTr bacilli may
escape host defense by restricting IFN--induced NO production, resisting nitrogen toxic radicals, and limiting
phagosome fusion with lysosomes.
Fast-growing mycobacteria have increasingly been recog-
nized as a human pathogen rather than mere colonizers.
Among the rapidly growing mycobacteria found in abundance
in the environment, strains associated with human diseases are
restricted mainly to the Mycobacterium fortuitum-Mycobacte-
rium chelonae complex (42). Human diseases are most com-
monly caused by accidental inoculation of contaminated ma-
terials (16). Disseminated cutaneous lesions have been
frequently associated with immunosuppression (17, 18, 41). It
has been noted that treatment of infections due to nontuber-
culous mycobacteria remains difficult, in part because myco-
bacteria are resistant to many of the first-line tuberculosis
agents and in part because so few other agents are available for
therapy (40).
Mycobacterium virulence is variable, depending not only on
species but also on strains of a given species (3). Several studies
have shown that mycobacteria, which grow on a solid medium,
yield distinguishable colonial morphotypes. The smooth, flat,
transparent variant (SmTr) has been associated with greater
virulence (23, 31) and lower susceptibility to many antimicro-
bial agents, whereas the smooth, domed, opaque (SmOp) col-
ony is avirulent (31, 34). Few studies have compared the viru-
lence levels of different colonial variants of a single
Mycobacterium isolate (21, 22), and until now no study has
been performed to define M. fortuitum virulence determinants.
Pathogenic mycobacteria, if not destroyed by the host innate
immune defense, survive and multiply inside macrophages
(M) within membrane-bound compartments that do not acid-
ify and have a restricted ability to fuse with lysosomes (35).
Host cells can also participate in the effective phase of the
infection, acting in the modulation of innate and acquired
immune responses (13, 24). M increase their antimycobacte-
rial activity when activated by IFN- (29), a cytokine produced
by both natural killer cells and T helper-1 lymphocytes (39).
This activity implies the induction of microbicidal molecules
such as NO by M (1, 6, 10). Furthermore, it has been dem-
onstrated that IFN- associated with lipopolysaccharide (LPS)
can induce the maturation of Mycobacterium phagosomes to
phagolysosomes in mouse macrophages (32, 38).
In the present study, we postulated that the ability of myco-
bacteria to live inside phagosomes of infected M is dependent
on bacillus virulence. In order to investigate this possibility, we
used an in vitro assay to compare very close microorganisms,
the SmTr and SmOp of a single M. fortuitum isolate, with
regard to their ability to infect M, to inhibit M-induced
microbicidal molecules such as NO, and to restrict the fusion
of their vacuoles with lysosomes. In contrast to SmOp, the
more virulent SmTr M. fortuitum strain induced lower NO
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production in vitro by gamma interferon (IFN-)-activated M
as well as phagosomes with lower fusigenicity.
MATERIALS AND METHODS
Cells and culture medium. The mouse M cell line J774E clone (kindly
provided by P. D. Stahl, Washington University) was maintained at 37°C in 5%
CO2 in RPMI 1640 (Sigma, St. Louis, Mo.) supplemented with 10% fetal bovine
serum (HyClone, Logan, Utah, or Gibco, Rockville, Md.), 2.0 g of sodium
bicarbonate/liter, 25 mM HEPES, 1.8 M 6-thioguanine, 100 IU of penicillin/ml,
and 100 g of streptomycin/ml (Sigma).
Bacteria. The SmOp M. fortuitum variant was isolated from naturally infected
C57BL/6 mice. To obtain SmTr, nude nu/nu mice were inoculated intravenously
with 108 opaque colonial M. fortuitum variant bacteria. After 30 days of infection,
bacteria were harvested from the livers and spleens of infected nude nu/nu mice,
and only SmTr variant was grown on Middlebrook 7H10 agar plates (Difco
Laboratories, Detroit, Mich.) supplemented with 10% oleic acid-albumin-dex-
trose-catalase (Difco Laboratories). Aliquots of SmOp or SmTr mycobacteria
were frozen at 70°C. When required, the frozen samples were quickly thawed,
vortex mixed, and adjusted to the desired titer in cell culture medium. Both M.
fortuitum SmOp and SmTr variants were characterized by PCR. Briefly, a loopful
of mycobacteria was suspended in 0.4 ml of TET (10 mM Tris-HCl [pH 7.5], 1
mM EDTA) with 1% Triton X-100 and subjected to three cycles of boiling and
freezing at 20°C. Ten microliters of the lysates was used for the PCRs. This
procedure was based on the enzymatic amplification of the hsp65 gene, followed
by digestion with BstEII and HaeIII (36). Amplifications were performed in 50-l
volume reactions containing 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 1.5 mM
MgCl2, 10% glycerol, 200 M concentrations of deoxynucleoside triphosphates,
a 0.5 M concentration of each primer (Tb11 [5-ACCAACGATGGTGTCCA
T] and Tb12 [5-CTTGTCGAACCGCATACCCT]), and 1.25 U of Taq poly-
merase (Gibco, Grand Island, N.Y.). The amplification mixture was submitted to
an initial denaturation at 95°C for 10 min; followed by 45 cycles of denaturation
at 95°C for 1 min, annealing at 60°C for 1 min, and extension at 72°C for 1 min;
followed in turn by a final extension step at 72°C for 7 min.
Cell activation and infection. Cells (5  105 per ml) in complete medium
without antibiotics (infection medium) were plated in 24-well culture plates
(Costar, Cambridge, Mich.), containing or not containing 13-mm-diameter glass
coverslips (Glasste´cnica Imp., Sa˜o Paulo, Brazil), in duplicates or triplicates.
Before 24 h of M. fortuitum infection, J774 cells were pretreated or not pre-
treated with 50 to 400 IU of recombinant IFN- (rIFN-; PharMingen, San
Diego, Calif., or R&D Systems, Minneapolis, Minn.)/ml in the absence or pres-
ence of 1 mM aminoguanidine (AMG; Sigma), a competitive inhibitor of nitric
oxide synthase. For electron microscopy (EM) experiments, cells were plated in
plastic culture petri dishes (35 mm; Costar). Thereafter, M were infected for an
additional 24 h with SmOp or SmTr M. fortuitum strains at a 10:1 mycobacteri-
um/M ratio. At 24 h postinfection, M cultures were fixed with 2.5% glutar-
aldehyde in phosphate-buffered saline for 20 min, and then glass coverslips
containing infected cells were allowed to air dry and were Ziehl-Neelsen stained
as previously described (8). To determine the percentage of infected cells, trip-
licate coverslips for each treatment group were examined by light microscopy
(magnification, 1,000), and at least 200 M were counted per coverslip.
Evaluation of bacillus viability. At 24 h postinfection, culture supernatants
were gently collected and infected J774 cells were washed twice with warm RPMI
1640 medium supplemented with 25 mM HEPES to remove noninternalized
mycobacteria. In order to liberate intracellular bacilli, infected J774 cells were
detached, counted, and then lysed by addition of saline containing 0.05% sodium
dodecyl sulfate (SDS) and protease inhibitors (p-nitrophenyl p-guanidinoben-
zoate, phenylmethylsulfonyl fluorete, N-p-tosyl-L-lysine chloromethyl ketone,
and N-tosyl-L-phenylanine chloromethyl ketone) (Sigma) for 20 min at room
temperature (RT). The number of viable mycobacteria per dish was determined
by plating serial 10-fold dilutions of cell lysates on Middlebrook 7H10 agar
(Difco Laboratories). Colonies were counted after incubation at 37°C for 10 to
15 days, and the results were expressed as the number of CFU per 105 cells.
Measurement of NO2. To detect NO production by M, its stable end
product, the NO2 content was determined by Griess reaction (15). Briefly,
conditioned medium was collected and centrifuged (12,000  g) for 3 min.
Aliquots (50 l) of conditioned medium were then distributed in a 96-well
microtiter plate (Costar), and equal volumes of Griess reaction solution (1%
sulfanilamide and 0.1% naphthyl-ethylenediamine in 2.5% phosphoric acid)
were added. The reaction was allowed to proceed for 10 min at RT, and the
optical density at 540 nm was measured. The amounts of NO in the samples were
calculated by extrapolation from a sodium nitrite standard curve prepared for
each experiment.
Quantification of phagosome-lysosome fusion by EM. In order to label cell
lysosomes, M were incubated with 15 nM bovine serum albumin conjugated to
colloidal gold particles (BSA-gold) for 3 h, and then the cells were washed,
activated or not activated with IFN- as described above, and chased for an
additional 18 h in infection medium at 37°C and 5% CO2. At 24 h postinfection,
the cells were fixed and processed for EM as previously described (14). Briefly,
infected cells were fixed at 4°C with 2.5% glutaraldehyde (Polyscience, War-
rington, Pa.) in 0.1 mM cacodylate buffer (pH 7.2) plus 0.1 M sucrose, 5 mM
CaCl2, and 5 mM MgCl2 (Sigma). After a 1-h treatment with wash buffer, cells
were postfixed for 1 h at RT with 1% osmium tetroxide in 0.1 mM cacodylate
buffer devoid of sucrose. They were then scraped off, concentrated in 2% agar in
cacodylate buffer, and treated for 1 h at RT with 1% uranyl acetate in Veronal
buffer. Samples were dehydrated in a graded series of acetone solutions and
embedded in Epon. Thin sections were sequentially stained with 2% uranyl
acetate in distillate water and lead citrate. As previously described, EM counting
of BSA-gold-labeled phagosomes that fused with lysosomes was performed to
assess fusion (11). Briefly, we performed two cuts 10 m apart from each other,
and at least 150 phagosomes were counted. Phagosome fusion with lysosomes
was considered when at least one BSA-gold particle was found inside the vacu-
oles.
NO-releasing agent treatment. An NO-releasing agent, SNAP (S-nitroso-N-
acetyl-DL-penicillamine), was purchased from Calbiochem (La Jolla, Calif.).
SNAP was dissolved in dimethyl sulfoxide (Sigma) at a concentration of 100 mM,
stored at 20°C, and freshly dissolved and diluted with RPMI 1640 immediately
before addition to the cultures. Prior to 24 h of infection, 100 M SNAP was
added to the cultures.
Statistical analysis. All experiments were done in duplicate or triplicate and
independently repeated at least three times. The results of the experiments were
expressed as the mean 	 the standard error of the mean (SEM) of three or more
experiments. The Student t test or one-way analysis of variance (ANOVA) was
used to analyze significance. Linear regression analysis was used to determine the
correlation between intracellular bacillus viability and NO production in re-
sponse to different IFN- concentrations. A P value of 
0.05 was considered
significant.
RESULTS
Intracellular uptake of M. fortuitum SmOp and SmTr vari-
ants was similar in J774 cells. The SmOp and SmTr ability to
infect resting J774 cells was evaluated. Cells were incubated
with SmOp or SmTr variant, and 24 h later the percentage of
infected cells was determined by optical microscopic counting.
As shown in Fig. 1A, the percentages of SmOp- and SmTr-
infected cells were similar: 76.2% 	 3.1% for SmOp-infected
cells and 80.3% 	 5.1% for cells infected with SmTr bacilli.
Although the percentages of M infected with either SmOp
or SmTr were similar, the infective capacity could only be
assessed by determining the number of intracellular viable
bacilli. At 24 h postinfection, cells were lysed to release intra-
cellular mycobacteria, and an aliquot of the Mycobacterium-
containing medium was serially diluted and plated on Middle-
brook agar. Although there were 2.5 more SmTr (5.4 	 2.3
CFU/105 M) than SmOp (2.2 	 0.7 CFU/105 M) intracel-
lular viable bacilli, this difference was not statiscally significant
(Fig. 1B).
SmOp variant potentialized NO production by IFN--
treated J774 cells. The ability of reactive nitrogen intermedi-
ates, such as NO, to inhibit Mycobacterium growth is contro-
versial (2, 5) and has not been investigated in the control of
fast-growing mycobacteria. The capacity of SmOp and SmTr
variants to induce NO production by activated J774 M cell
line was examined. To induce NO, cells were treated with
different concentrations of rIFN-, which ranged from 50 to
400 IU/ml, for 18 h and then infected with SmOp or SmTr
colonies. At 24 h postinfection, the NO2 content was deter-
mined by using the Griess reaction. Control nonstimulated
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cells infected with SmOp (0.8 	 0.5 M) or SmTr (0.5 	 0.3
M) variants produced insignificant nitrite levels (Fig. 2).
IFN- treatment greatly increased NO production only by cells
infected with SmOp Mycobacterium variant (Fig. 2). Indeed,
the amount of IFN--induced NO production by J774 cells was
4.8 to 9.0 times higher with SmOp (23.1 to 37.7 M) compared
to SmTr infection (3.9 to 4.8 M; P  0.0332). Interestingly,
NO levels produced by SmTr-infected cells pretreated with
IFN- were similar to the levels produced by control nonin-
fected IFN--treated J774 cells (3.8 	 1.2 M, n  8), indi-
cating that only the SmOp variant potentialized IFN--induced
nitrogen radical production.
NO production by rIFN--treated J774 cells resulted from
iNOS activity, since 1 mM AMG completely abrogated NO
production by activated M infected with either M. fortuitum
SmOp or SmTr (0.9 	 0.4 or 1.6 	 0.4 M, respectively).
IFN--induced NO reduced SmOp uptake. To determine
whether IFN--induced NO production by M had any effect
on the capacity to infect cells, we measured the percentage of
infection and intracellular viability of SmOp or SmTr myco-
bacteria by adding rIFN- associated or not associated with
AMG. Neither rIFN- addition nor NO inhibition affected the
percentage of both SmOp- and SmTr-infected M (Fig. 3A).
Intracellular viability of the two variants was then assessed in
control and IFN--treated cells. IFN- treatment decreased
SmOp viability in seven of eight experiments. However, the
reduction of 35.8% 	 7.0% (n  8) in viability was not statis-
tically significant compared to nontreated controls. AMG was
then added to rIFN--treated cells, and CFU were determined
24 h postinfection. Interestingly, NO inhibition led to increases
of 88.4% 	 43.8% in SmOp intracellular viability compared to
bacillus viability in control nontreated M and of 169.4% 	
66.3% compared to cells only pretreated with IFN- (P 
0.0075, ANOVA), indicating NO participation in SmOp IFN-
-induced killing (Fig. 3B). A quantitative assessment of the
strength of the association between SmOp intracellular viabil-
ity and NO production in response to different IFN- concen-
trations was made via linear regression analysis. The reduction
in SmOp intracellular viable bacilli in the first moment after
infection was highly correlated with the level of produced NO
by IFN--stimulated J774 cells (r 0.9961 and P 0.0039; Fig.
3C). On the other hand, SmTr viability was not affected by
treatment with either IFN- alone or IFN- plus AMG (Fig.
3B), and there was no correlation between the numbers of
SmTr intracellular bacilli and NO production in response to
IFN- treatment (r  0.1293 and P  0.6737), indicating SmTr
prevention to induce reactive nitrogen radicals (Fig. 3D).
Since rIFN--induced NO had a consistent but slight effect
on SmOp and no effect on SmTr infection, we sought to de-
termine whether higher NO concentrations could decrease
intracellular Mycobacterium viability. To address this issue,
cells were treated with SNAP, an exogenous NO donor. At
24 h postinfection, the NO concentration achieved higher lev-
els in SNAP-treated cells than in rIFN--treated cells (108.7
M [n  5] and 208.5 M [n  2] for SmTr and SmOp,
respectively). SNAP treatment reduced SmOp intracellular vi-
FIG. 1. Intracellular uptake of M. fortuitum SmOp and SmTr was
similar in J774 cells. (A) Percentage of M. fortuitum SmOp- or SmTr-
infected J774 cells. Cells were infected with SmOp or SmTr bacilli at
a ratio of 10:1 and, 24 h later, fixed and Ziehl-Neelsen stained. Mi-
croscopic counting was performed to determine the percentage of
SmOp- or SmTr-infected cells (P  0.4892). Bars represent the mean
	 the SEM of 12 and 5 independent experiments with SmOp and
SmTr, respectively. (B) SmOp or SmTr viability in nonstimulated M.
Cells were infected as described above and lysed 24 h later. Cell
supernatants were then serially diluted and plated in 7H10 Middle-
brook medium. The M. fortuitum viability was determined by CFU
counts after 10 days of plate incubation (P  0.1565). Bars represent
the mean 	 the SEM of eight independent experiments with SmOp
and six independent experiments with SmTr. P values were determined
by the Student t test.
FIG. 2. M. fortuitum SmOp and SmTr induced different levels of
NO production by infected J774 cells. Cells were treated with different
concentrations of rIFN- (50 to 400 IU/ml) for 18 h and then infected
with SmOp or SmTr colonies. At 24 h postinfection, cell supernatants
were collected, and the NO2 concentrations were determined by
using the Griess reaction (P  0.0332, ANOVA). Control cells treated
with 100 IU of rIFN-/ml produced 3.8 	 1.2 M (n  8) NO2. The
bars represent the mean 	 the SEM of (n) independent experiments.
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ability by 70.7% 	 29.3% (n  2) compared to control cells.
On the other hand, SmTr viability was even slightly higher
(21.5% 	 48.0, n  5) in response to elevated NO concentra-
tions in SNAP-treated cells.
SmOp and SmTr colonies induced phagosomes with differ-
ent fusion capacities in the J774 cell line. EM observations
showed that there were morphological differences between
SmOp- and SmTr-induced phagosomes. SmOp bacteria were
found in large phagocytic vacuoles, whereas the SmTr bacilli
were observed within tight phagosomes (Fig. 4). Since it has
been demonstrated that Mycobacterium survival is related to
restricted phagosome-lysosome fusion (35), we sought to de-
termine whether there were differences between SmOp- and
SmTr-induced phagosomes with regard to their ability to fuse
with lysosomes. EM counting of BSA-gold-labeled phago-
somes that fused with lysosomes was performed to assess fu-
sion. Interestingly, the extent of fusion of SmOp variant-con-
taining phagosomes with lysosomes was 69% higher than for
those induced by SmTr colonies in resting M (P  0.0409)
(Fig. 5). Surprisingly, although IFN--induced NO production
was able to reduce SmOp viability, IFN- addition to the
cultures did not modify the fusion ability of either SmOp- or
SmTr-containing phagosomes with lysosomes. In addition,
AMG added to IFN--treated cells did not modify phagosome-
lysosome fusion despite the restoration of SmOp intracellular
viability (Table 1).
DISCUSSION
In the present study we used an in vitro assay to compare
M responses to two different M. fortuitum colony morpho-
types, taking advantage of the fact that they were derived from
FIG. 3. IFN--induced NO reduced SmOp uptake. (A) Percentage of J774 infected cells, treated or not treated with either rIFN- (100 IU/ml)
alone or with rIFN- plus AMG (1 mM). Cells were treated, infected, and stained as indicated in the legend for Fig. 1. The P values were 0.4669
for SmOp-infected cells and 0.2623 for SmTr-infected cells (ANOVA; n  number of experiments). (B) SmOp or SmTr viability in J774 cells
pretreated with rIFN- alone or with rIFN- plus AMG. Cells were infected and lysed, and cell supernatants were plated in agar as indicated in
the legend for Fig. 1. Control viability was considered 100% (2.2 	 0.7 CFU/105 cells for SmOp-infected cells and 5.4 	2.3 CFU/105 cells for
SmTr-infected cells). The results represent the percentage of viability related to control cells (P  0.0075 and P  0.7066 [ANOVA] for SmOp
and SmTr, respectively). The bars represent the mean 	 the SEM of six independent experiments for SmOp-infected cells and eight independent
experiments for SmTr-infected cells. (C) A strong linear correlation between NO produced by SmOp-infected J774 cells pretreated with 50 to 200
IU of IFN-/ml and the number of intracellular viable bacilli (CFU/105 cells) was demonstrated. Each point represents the mean of two to eight
independent experiments (r  0.9961 and P  0.0039). (D) Absence of linear correlation between NO produced by SmTr-infected J774 cells
pretreated with 100 IU of IFN-/ml and the number of intracellular viable bacilli (CFU/105 cells). Each point represents one experiment (n  13,
r  0.1293, and P  0.6737).
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the same isolate. The association of distinct colonial morpho-
types and bacillus virulence has been already described, al-
though most of the observations compared relative virulence
from different isolates (9, 23, 30). In the present study, the
more virulent SmTr morphotype was converted from an SmOp
M. fortuitum that has been used to infect nu/nu BALB/c mice.
As demonstrated for both M. avium and M. tuberculosis (25–27,
31, 33, 34), we showed that the M. fortuitum variants described
here also displayed distinct virulence profiles. Virulence de-
pended, at least in part, on the capacity of bacilli to prevent
NO production by activated M and on the nature of the
compartment they induced in infected M. The possible mech-
anisms to explain these differences have not been investigated
but may be associated with distinct cell wall components, such
as acidic polysaccharide present in the virulent bacillus that is
absent in the avirulent bacillus and in the recently described
virulent bacillus inhibition of signaling pathways that results in
decreased production of host mycobacterial killing mecha-
nisms (28, 37).
Both M. fortuitum SmOp and SmTr variants were able to
infect the J774 M cell line. Although we detected almost
three times more SmTr intracellular viable mycobacteria than
SmOp bacilli in infected M, this difference was not statisti-
cally significant. Previous studies comparing macrophage abil-
ity to phagocytose mycobacteria displaying distinct virulence
showed no differences at 24 h postinfection in M ability to
take up bacilli and in the number of intracellular viable bacilli.
At 4 to 7 days after infection, however, the number of virulent
mycobacteria was higher than the number of avirulent myco-
bacteria (9, 10, 21, 26). Since our aim was to study the early
stages of infection, we did not evaluate later times and cannot
exclude that similar differences exist in our in vitro model.
We showed for the first time that SmOp and SmTr variants
induced different levels of NO production by IFN--stimulated
M and that IFN- treatment only reduced SmOp intracellu-
lar viability. Indeed, IFN--induced NO production by cells
infected with avirulent bacilli was significantly greater than by
cells infected with virulent mycobacteria and decreased by 36%
the intracellular viability of SmOp variant, an effect completely
reverted by AMG. Furthermore, the amount of NO produced
by cells treated with IFN- strongly correlated with a decrease
in SmOp intracellular viability (r  0.9961 and P  0.0039). In
FIG. 4. Ultrastructural characterization of SmOp- and SmTr-induced phagosomes. To label lysosomes, J774 cells were incubated with 15-nm
BSA-gold for 3 h and then washed and infected with SmOp or SmTr variants of M. fortuitum. At 24 h postinfection, cells were fixed and processed
for EM as indicated in Material and Methods. (A and B) J774 cells infected with SmOp in phagosomes that fuse with BSA-gold labeled lysosomes.
(C and D) J774 cells infected with SmTr inside phagosomes that restrict fusion with lysosomes. Arrows (panels A and B), BSA-gold inside
phagolysosomes; arrowheads (panels A and D), BSA-gold inside lysosomes; P, phagosomes; P-L, phagolysosomes; L, lysosomes.
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addition, SmOp and not SmTr intracellular viability was af-
fected in the presence of higher NO concentrations. Together,
these data suggest that SmTr virulence depends on SmTr pre-
vention to induce reactive nitrogen intermediates by M. It is
possible that ligands present in the SmOp cell wall but absent
in the SmTr cell wall interact with receptors in the M surface
and then transduce a second signal responsible for induction of
higher NO production. In addition, this interaction can induce
M to produce cytokines known to potentialize NO produc-
tion by M (19, 20). In SmTr resistance to nitrogen interme-
diates, it has been demonstrated that M. avium-M. intracellu-
lare complex strains and a pathogenic M. tuberculosis isolate
express the noxRI gene that confers bacillus resistance to re-
active nitrogen intermediates (12).
In experiments to determine the nature of SmOp- and
SmTr-induced phagosomes, we demonstrated that, by 24 h
postinfection, 69% more phagosome-containing SmOp bacilli
had fused with lysosomes versus the SmTr-induced phago-
somes. These data demonstrated that SmTr-containing phago-
somes, compared to SmOp-induced phagosomes, more
strongly restricted fusion with lysosomes. Our data are in
agreement with studies showing that phagosome-containing
dead bacilli have greater fusion capacity than those containing
live mycobacteria (4, 7) and that pathogenic mycobacteria pri-
marily reside in nonacidified, nonlysosomal compartments
(38). In this report the avirulent M. fortuitum variant lived in
phagosomes that progressed more rapidly through the endo-
cytic pathway to fuse with lysosomes than the virulent variant.
It is important to note that phagosomes containing the virulent
M. fortuitum bacilli displayed greater fusion capacity with ly-
sosomes compared to what has been described about fusion
capacity of phagosomes containing M. tuberculosis or M. avium
(35, 43). This can be explained by the fact that these mycobac-
teria are known to be more virulent than M. fortuitum. To-
gether, these data suggest that fusion capacity with lysosomes
is an important parameter to define not only Mycobacterium
viability (38) but also the virulence of mycobacteria derived
from the same isolate.
Neither the addition of IFN- nor the inhibition of NO
production by AMG modified the fusion ability of virulent and
avirulent phagosomes with lysosomes. Schaible et al. (32) dem-
onstrated that the addition of IFN- and lipopolysaccharide to
M. avium-infected cells induced phagosomes that reduced in-
traphagosomal pH in correlation with an increased accumula-
tion of proton-ATPases without any change in Mycobacterium
viability. These authors concluded that in their system the
functional translocation toward more lysosomal compartments
appeared to precede any marked drop in microbial viability,
suggesting that IFN- plus lipopolysaccharide-induced phago-
some-lysosome fusion is the product of an alteration in M
physiology rather than a consequence of microbial death (32).
Our results indicate that in cells infected with avirulent SmOp,
NO produced in response to IFN--mediated activation was
able to inhibit intracellular bacillus viability before any en-
hancement in phagosomal fusigenicity with lysosomal compart-
ments. Furthermore, by 24 h postinfection with virulent SmTr
M. fortuitum, IFN- treatment neither modified bacillus viabil-
ity nor phagosome fusion with lysosomes. The differences be-
tween our findings and the previous study (32) may be due to
the use of different Mycobacterium species with different viru-
lence profiles.
In conclusion, we demonstrated for the first time that in an
early phase of infection virulent bacilli, in contrast to avirulent
bacilli, from a single isolate escape host defense by resisting NO,
failing to induce nitrogen toxic radicals, and restricting phago-
some maturation to phagolysosomes, host responses known to
be important for controlling Mycobacterium infection.
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